ArticleCancer biology & therapy2022

Feasibility and safety of targeting mitochondria for cancer therapy - preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor.

Umar Hayat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.